Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

By G. Comi, M. Filippi, Frederik Barkhof, L. Durelli, G. Edan, Ó. Fernández, H. Hartung, P. Seeldrayers, P. Sørensen, M. Rovaris and 2 more. The Lancet, 2001

1,101 citations recorded by the source corpus.

Subfields: Neurology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/5afe8eb764958aedb159609e066c7b3fa8a88243

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. Wolfgang Brück
2. B. Weinshenker
3. Hans Lassmann

In Pathology and Forensic Medicine

1. Jeffrey A. Cohen
2. Wolfgang Brück
3. B. Weinshenker
4. Hans Lassmann
5. C. Iadecola
6. J. Buckner

Citations in the corpus

• Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. (2002, result): “This is in agreement with clinical studies that showed a bene®t of immunomodulatory treatment with b-interferon starting early after disease onset (Jacobs et al., 2000; Comi et al., 2001).”
• Differential diagnosis of suspected multiple sclerosis: a consensus approach (2008, background): “, a patient with acute optic neuritis and Lhermitte’s sign or a patient with optic neuritis who also has an extensor plantar response) [7,8].”
• Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. (2002, methodology): “A 2-year placebo-controlled trial of b-interferon, which demonstrated a delay in the primary outcome (time to development of clinically de®nite multiple sclerosis; Comi et al., 2001), also demonstrated signi®cant brain atrophy in the placebo arm over the course of the trial (Filippi et al.”
• Type I interferon inhibits interleukin-1 production and inflammasome activation. (2011, background): “In such circumstances, an immunosuppressive role of a- and b-IFNs was suggested by several reports (Decker et al., 2005; Jensen et al., 1992; Shahangian et al., 2009).”
• Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. (2008, background): “Immunomodulatory treatment with beta interferon in CIS patients with abnormal MRI for up to over 3 years decreases the number of new MRI lesions, delays development of CD multiple sclerosis (Jacobs et al., 2000; Comi et al., 2001; Kappos et al., 2006], and possibly slows development of early disabil”